Johnson & Johnson said on Wednesday its experimental psoriasis drug has shown superior skin clearance compared to Bristol ...

New research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025 reveals that people with ...

Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% ...

New research presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2025 reveals that people ...

Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% ...

Momentum started building behind icotrokinra last year when J&J posted results from another phase 3 trial, dubbed Iconic-Lead ...

Johnson & Johnson's icotrokinra outperforms competing psoriasis treatments in late-stage trials, showing greater efficacy and ...

UCB, a global biopharmaceutical company, today announced three- and four-year data from across the open-label extension (OLE) Phase 3 trials for BIMZELX® (bimekizumab-bkzx) in moderate-to-severe ...

Paris, France, Thursday, 18 September 2025) New research presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2025 ...

Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% lower risk ...

Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-ADVANCE 1 and 2 studies which assessed the superiority of icotrokinra, a first-in-class investigational targeted oral ...

Johnson & Johnson and Protagonist Therapeutics announced new data from their Phase 3 studies to treat severe plaque psoriasis ...